Patient-derived pancreatic cancer organoids showed significant growth inhibition when treated with decitabine, an epigenetic inhibitor. Noticeably, the combination of decitabine with a PARP inhibitor showed pronounced synergism in inhibiting tumour organoid growth. By employing the 6-base genome via duet evoC, Zachery Keepers and researchers at the University of Maryland have identified differentially methylated genes that may be responsible for therapy resistance and tumour aggression in pancreatic cancer.